Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes.
We tested the hypothesis that primary cultures of human hepatocytes could predict potential drug interactions with methadone and buprenorphine. Hepatocytes (five donors) were preincubated with dimethyl sulfoxide (DMSO) (vehicle), rifampin, or nelfinavir before incubation with methadone or buprenorphine. Culture media (0-60 min) was analyzed by liquid chromatography-tandem mass spectrometry for R- and S-methadone and R- and S-2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) or for buprenorphine, norbuprenorphine, and their glucuronides [buprenorphine-3-glucuronide (B-3-G) and norbuprenorphine-3-glucuronide (N-3-G)]. R- and S-EDDP were detected in three of five, four of five, and five of five media from cells pretreated with DMSO, nelfinavir, and rifampin. R-EDDP increased 3.1- and 26.5-fold, and S-EDDP increased 2.5- and 21.3-fold after nelfinavir and rifampin. The rifampin effect was significant. B-3-G production was detected in media of all cells incubated with buprenorphine and accounted for most of the buprenorphine loss from culture media; it was not significantly affected by either pretreatment. Norbuprenorphine and N-3-G together were detected in three of five, four of five, and five of five donors pretreated with DMSO, nelfinavir and rifampin, and norbuprenorphine in one of five, one of five, and two of five donors. Although there was a trend for norbuprenorphine (2.8- and 4.9-fold) and N-3-G (1.7- and 1.9-fold) to increase after nelfinavir and rifampin, none of the changes were significant. To investigate low norbuprenorphine production, buprenorphine was incubated with human liver and small intestine microsomes fortified to support both N-dealkylation and glucuronidation; N-dealkylation predominated in small intestine and glucuronidation in liver microsomes. These studies support the hypothesis that methadone metabolism and its potential for drug interactions can be predicted with cultured human hepatocytes, but for buprenorphine the combined effects of hepatic and small intestinal metabolism are probably involved.
Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84108, USA. david.moody@utah.edu
David E
DE
Moody
Wenfang B
WB
Fang
Shen-Nan
SN
Lin
Denise M
DM
Weyant
Stephen C
SC
Strom
Curtis J
CJ
Omiecinski
D000328:Adult; D000368:Aged; D000701:Analgesics, Opioid / Q000378:metabolism*; D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D001711:Biotransformation; D002047:Buprenorphine / Q000031:analogs & derivatives / Q000378:metabolism*; D002478:Cells, Cultured; D002853:Chromatography, Liquid; D003640:Dealkylation; D004347:Drug Interactions; D005260:Female; D020719:Glucuronides / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D007700:Kinetics; D008297:Male; D008691:Methadone / Q000378:metabolism*; D008862:Microsomes, Liver / Q000378:metabolism; D008875:Middle Aged; D019888:Nelfinavir / Q000494:pharmacology*; D011759:Pyrrolidines / Q000378:metabolism; D012293:Rifampin / Q000494:pharmacology*; D021241:Spectrometry, Mass, Electrospray Ionization; D053719:Tandem Mass Spectrometry
D000701:Analgesics, Opioid; D000904:Antibiotics, Antitubercular; D020719:Glucuronides; D017320:HIV Protease Inhibitors; D011759:Pyrrolidines; C499393:norbuprenorphine-3-beta-D-glucuronide; C050182:buprenorphine-3-O-glucuronide; D002047:Buprenorphine; C043585:norbuprenorphine; D019888:Nelfinavir; D008691:Methadone; D012293:Rifampin; C010724:2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine